Q4 Earnings Estimate for CADL Issued By HC Wainwright

Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Investment analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for Candel Therapeutics in a report released on Friday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.22) per share.

Other research analysts also recently issued research reports about the company. Jefferies Financial Group initiated coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 target price for the company. Zacks Research lowered Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Canaccord Genuity Group decreased their price target on Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 13th. Finally, UBS Group reissued a “buy” rating on shares of Candel Therapeutics in a report on Monday, August 17th. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.29.

Get Our Latest Analysis on Candel Therapeutics

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $5.40 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.57 and a current ratio of 7.57. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00. The firm has a market cap of $423.63 million, a price-to-earnings ratio of -3.65 and a beta of -0.27. The business’s fifty day moving average is $9.47 and its 200 day moving average is $8.39.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CADL. Portolan Capital Management LLC increased its holdings in shares of Candel Therapeutics by 1.4% in the third quarter. Portolan Capital Management LLC now owns 3,538,561 shares of the company’s stock worth $36,943,000 after purchasing an additional 48,163 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Candel Therapeutics by 4.1% in the third quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock worth $3,316,000 after buying an additional 12,385 shares in the last quarter. Cetera Investment Advisers purchased a new stake in shares of Candel Therapeutics in the third quarter worth $124,000. Entropy Technologies LP bought a new stake in Candel Therapeutics during the third quarter valued at $266,000. Finally, Jump Financial LLC boosted its stake in Candel Therapeutics by 22.2% during the third quarter. Jump Financial LLC now owns 130,579 shares of the company’s stock valued at $1,363,000 after buying an additional 23,739 shares during the period. 13.93% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Candel Therapeutics

These are some of the CADL headlines that stood out recently:

  • Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
  • Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
  • Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Featured Articles

Earnings History and Estimates for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.